These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2496369)

  • 1. Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study.
    Herait P; Rougier P; Theodore C; Kac JL; Droz JP
    Oncology; 1989; 46(2):88-90. PubMed ID: 2496369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.
    J Clin Oncol; 1986 Dec; 4(12):1794-8. PubMed ID: 2946815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
    Engstrom PF; MacIntyre JM; Mittelman A; Klaassen DJ
    Am J Clin Oncol; 1984 Aug; 7(4):313-8. PubMed ID: 6377866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
    Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
    Okabe S; Ishikawa T; Tanami H; Kuwabara H; Fukahara T; Udagawa M; Ootsukasa S; Arai T; Maruyama S; Murase N; Yamashita H; Iwai T
    J Med Dent Sci; 2002 Jun; 49(2):77-84. PubMed ID: 12627817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association.
    Richards F; Case LD; White DR; Muss HB; Spurr CL; Jackson DV; Cooper MR; Zekan P; Cruz J; Stuart JJ
    J Clin Oncol; 1986 Apr; 4(4):565-70. PubMed ID: 3514806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C].
    Migeod F; Gerlach D; Kress M; Hoffmann W; Farroukh R; Seeber S
    Onkologie; 1988; 11 Suppl 2():14-20. PubMed ID: 3146743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Fluorouracil, high-dose folinic acid, and mitomycin C combination chemotherapy in advanced gastrointestinal adenocarcinomas. A pilot study.
    Becouarn Y; Brunet R; Bussières E; Marée D
    Oncology; 1988; 45(4):269-72. PubMed ID: 3133620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of dacarbazine, mitomycin C, 5-fluorouracil and vincristine in advanced colorectal cancer.
    Falkson G; Pretorius HL; Falkson HC; Schoeman HS
    Cancer Chemother Pharmacol; 1983; 11(3):203-4. PubMed ID: 6416696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inefficacy of dacarbazine, mitomycin C, and hepatic irradiation in patients with metastatic adenocarcinoma of the gastrointestinal tract.
    Smith BJ; Evans M; Hellmann K; Jones R; Newton K; Peters N; Phillips RH
    J Clin Oncol; 1984 Jun; 2(6):578-80. PubMed ID: 6427420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Beerblock K; Rinaldi Y; André T; Louvet C; Raymond E; Tournigand C; Carola E; Favre R; de Gramont A; Krulik M
    Cancer; 1997 Mar; 79(6):1100-5. PubMed ID: 9070486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer.
    Ross P; Norman A; Cunningham D; Webb A; Iveson T; Padhani A; Prendiville J; Watson M; Massey A; Popescu R; Oates J
    Ann Oncol; 1997 Oct; 8(10):995-1001. PubMed ID: 9402173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.
    Rosati G; Rossi A; Reggiardo G; Manzione L
    Oncology; 2002; 62(3):209-15. PubMed ID: 12065867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
    Bamias A; Papamichael D; Syrigos K; Pavlidis N
    J Chemother; 2003 Jun; 15(3):275-81. PubMed ID: 12868555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
    J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II evaluation of 5-fluorouracil, folinic acid and cisplatin in advanced-stage colorectal adenocarcinoma.
    Scheithauer W; Depisch D; Schiessel R; Ludwig H
    Oncology; 1989; 46(4):217-21. PubMed ID: 2787010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
    BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
    O'Dwyer PJ; Paul AR; Walczak J; Weiner LM; Litwin S; Comis RL
    J Clin Oncol; 1990 Sep; 8(9):1497-503. PubMed ID: 2391557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FAM (5-fluorouracil, doxorubicin, and mitomycin) plus triazinate (FAM-T) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization.
    Ahlgren JD; Smith FP; Cazap E; Estevez RA; Marantz A; Woolley PV; Wilcosky T; Stein J; Schein PS
    Cancer Treat Rep; 1987 Apr; 71(4):419-20. PubMed ID: 3548959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.